Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis
- 1 August 1994
- journal article
- clinical trial
- Published by Elsevier in Fertility and Sterility
- Vol. 62 (2) , 246-250
- https://doi.org/10.1016/s0015-0282(16)56873-3
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Gonadotropin releasing hormone agonist therapy and its effect on bone massGynecological Endocrinology, 1991
- THE EFFECTS OF NAFARELIN AND DANAZOL ON VERTEBRAL TRABECULAR BONE MASS IN PATIENTS WITH ENDOMETRIOSISClinical Endocrinology, 1990
- Bone Mass Reduction after Estrogen Deprivation by Long-Acting Gonadotropin-Releasing Hormone Agonists and Its Relation to Pretreatment Serum Concentrations of 1,25-Dihydroxyvitamin D3Journal of Clinical Endocrinology & Metabolism, 1990
- Direct effects of 17 beta-estradiol on trabecular bone in ovariectomized rats.Proceedings of the National Academy of Sciences, 1990
- Effects of nafarelin on bone densityAmerican Journal of Obstetrics and Gynecology, 1990
- Reduced Bone Mass in Reproductive-Aged Women with Endometriosis*Journal of Clinical Endocrinology & Metabolism, 1989
- Bone mineral density of the spine and proximal femur in normal and osteoporotic subjects in JapanBone and Mineral, 1989
- The Effect of a Gonadotropin-Releasing Hormone Agonist Analog (Nafarelin) on Bone MetabolismJournal of Clinical Endocrinology & Metabolism, 1988
- REVERSIBLE TRABECULAR BONE DENSITY LOSS FOLLOWING INDUCED HYPO‐OESTROGENISM WITH THE GnRH ANALOGUE BUSERELIN IN PREMENOPAUSAL WOMENClinical Endocrinology, 1988
- LHRH ANALOGUES AND BONE LOSSThe Lancet, 1987